Results 221 to 230 of about 218,137 (295)

Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget’s Disease

Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget’s Disease
2021年度
openaire  

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Sarcomatoid Lung Carcinoma Successfully Treated With Combined Cytotoxic Chemotherapy and Anti-Programmed Death-Ligand 1 (Anti-PD-L1) Antibodies. [PDF]

Cureus
Yoshimine K, Tobino K, Ota H, Hiramatsu Y, Yamamoto R.   +4 more
europepmc   +1 more source

Targeting Supramolecular Active Complexes of Nav1.7/Nav1.8 to Relieve Chronic Neuropathic Pain

Advanced Science, EarlyView.
In mice and patients with severe chronic neuropathic pain (NP), Nav1.7, Nav1.8, TrkB, and five cytoskeletal proteins form supramolecular active complexes (SMACs) with polygonal lattice structures as noxious signal amplifiers in dorsal root ganglion (DRG) neurons.
Liting Sun, Hang Xian, Yunxin Shi, Taotan Yang, Hongyan Shuai, Wenchao Hu, Siying Fei, Miao Xu, Taoyuan Yang, Ruilong Xia, Ting Wen, Fengting Zhu, Yan Fu, Yang Li, Wei Xia, Ran Qian, Yuanying Liu, Zhicheng Tian, Lamei Li, Qian Zhou, Lize Xiong, Rui Cong, Ceng Luo, Shengxi Wu, Xiafeng Shen, Xin Yu, Rou‐Gang Xie, Changgeng Peng   +27 more
wiley   +1 more source

Programmed Death-Ligand 1 Expression across Multiple Assays in Ovarian Cancer: A Comparative Analysis. [PDF]

Cancer Res Treat
Jang EB, So KA, Kim WY, Lim SD, Kim TJ, Bang H, Kim WS.   +6 more
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study. [PDF]

J Vet Med Sci
Takagi S, Tagawa M, Maekawa N, Konnai S, Kagawa Y, Hosoya K, Yamauchi A, Kudo A, Kamo S, Kim S, Kinoshita R, Deguchi T, Owaki R, Tachibana Y, Yokokawa M, Takeuchi H, Nakamura H, Kato Y, Kanazawa S, Abe T, Furuta T, Yamamoto K, Suzuki Y, Okagawa T, Murata S, Ohashi K.   +25 more
europepmc   +1 more source

SAA/FPR2 Signaling Between Pericentral Hepatocytes and Macrophages Exacerbates Zonated Liver Transplant Injury

Advanced Science, EarlyView.
After liver transplantation, ischemia‐reperfusion injury is more severe in pericentral regions. Multiomic analyses of human grafts and mouse models identify FOXO1 activation in pericentral hepatocytes as an upstream driver of SAA secretion. SAA recruits and activates FPR2+ macrophages, amplifying local inflammation. Amilo‐5MER inhibits SAA bioactivity,
Feng Zhang, Rong Li, Tingting Wang, Jianhao Zhang, Zhengqi Wu, Qiang You, Xuying Liu, Cuicui Xiao, Jiebin Zhang, Haitian Chen, Jiaqi Xiao, Jia Yao, Jun Zheng, Yingcai Zhang, Hua Li, Shuhong Yi, Yang Yang, Qi Zhang, Xiaofeng Yuan, Yasong Liu   +19 more
wiley   +1 more source

Concordance of programmed death-ligand 1 expression assessments determined <i>via</i> two immunohistochemical tests and the polymerase chain reaction method. [PDF]

World J Exp Med
Senchukova MA, Saidler NV, Zubareva EY, Prokofiev AB, Tagabilev DG.   +4 more
europepmc   +1 more source